Helena I. Boshoff

DDU384: A new preclinical candidate for the treatment of Tuberculosis

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis

The paper identifies and evaluates dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis, showing activity across multiple media and differential sensitivity in resistant strains.

Validating Conditionally Essential Targets: Discovery of the First Orally Effective Biotin Inhibitor against MycobacteriumTuberculosis

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

Fragment-based development of small molecule inhibitors targeting Mycobacterium tuberculosis cholesterol metabolism

This paper develops small molecule inhibitors targeting Mtb cholesterol oxidases CYP125 and CYP142, showing potent antimicrobial activity against drug-susceptible and MDR-TB strains.

Common biological features of Mycobacterium tuberculosis MmpL3 inhibitors

This study identifies common biological features of MmpL3 inhibitors, showing potent activity against M. tuberculosis and highlighting their potential as drug candidates.

Sanfetrinem, an oral beta-lactam antibiotic repurposed for the treatment of tuberculosis

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.

Environmental sphagnum-associated fungi target thiol homeostasis to compete with Mycobacterium tuberculosis.

The paper identifies sphagnum-associated fungi that produce antitubercular agents inducing thiol stress in Mycobacterium tuberculosis.